Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Clinical Trials Arena on MSN1d
BioCity and MSD to evaluate cancer treatment combination in Phase I/II trialBioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...
Pharmaceutical Technology on MSN2d
Vivace closes $35m in Series D for cancer drug developmentVivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...
Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...
Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
Centauri Therapeutics Limited has announced the selection of its first clinical candidate for the ABX-01 programme. The ...
Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ...
Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug candidate, PN6047, in a pre-IND meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback